Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5927
    -0.0008 (-0.13%)
     

  • NZD/EUR

    0.5541
    +0.0000 (+0.01%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.91
    -0.45 (-0.54%)
     

  • GOLD

    2,342.60
    +0.50 (+0.02%)
     

  • NASDAQ

    17,538.08
    +66.61 (+0.38%)
     

  • FTSE

    8,037.85
    -6.96 (-0.09%)
     

  • Dow Jones

    38,376.07
    -127.62 (-0.33%)
     

  • DAX

    18,064.54
    -73.11 (-0.40%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • NZD/JPY

    91.8210
    +0.0550 (+0.06%)
     

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks Equity Research
·2-min read

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Why Investors Should Pay Attention to This Value Stock

Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.

ADVERTISEMENT

Exelixis (EXEL)

San Francisco, CA-based Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers.

EXEL is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of B. Shares are currently trading at a forward P/E of 14.4X for the current fiscal year compared to the Medical - Biomedical and Genetics industry's P/E of 18.8X. Additionally, EXEL has a PEG Ratio of 0.4 and a Price/Cash Flow ratio of 20.6X. Value investors should also note EXEL's Price/Sales ratio of 3.3X.

Many value investors pay close attention to a company's earnings as well. For EXEL, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.19 to $1.11 per share for 2022. Per share EXEL boasts an average earnings surprise of 84.4%.

Investors should take the time to consider EXEL for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research